“We are delighted to have achieved the major landmark of a CE mark for Lightpoint’s first product offering: the LightPath™ Imaging System,” said Dr David Tuch, CEO of Lightpoint Medical. “Bringing LightPath™ to market is an important milestone in our efforts to transform cancer surgery.”
Cancer surgery is often unsuccessful because surgeons fail to remove all of the cancerous tissue. Today, surgeons rely on the look and feel of the tissue to detect cancer during surgery. The consequences, in addition to the need for a repeat operation, include delayed follow-up treatment, increased likelihood of recurrence, patient anxiety and enormous cost to health services.
Read more: PR Newswires